CGRP vs Neuropeptide FF — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide produced by alternative splicing of the calcitonin gene in neurons. It is the most abundant neuropeptide in the sensory nervous system, expressed in trigeminal ganglion neurons and released from perivascular n...
Calculate CGRP dose →Neuropeptide FF (NPFF) is an endogenous octapeptide first isolated from bovine brain in 1985 and recognized as a key endogenous anti-opioid system component. NPFF is produced in the hypothalamus, brain stem, and spinal cord and acts on NPFF1 and NPFF2 receptors (GPCRs) to oppose ...
Calculate Neuropeptide FF dose →| Parameter | CGRP | Neuropeptide FF |
|---|---|---|
| Category | Neuropeptide | Neuropeptide |
| Research | FDA Approved (Anti-CGRP antibodies) | Research |
| Half-Life | ~7-10 min (plasma; native) | Short (minutes) |
| Typical Dose | Anti-CGRP mAbs: 70-240 mg SC monthly or quarterly | 0.1-10 nmol (central, animal) |
| Frequency | Monthly or quarterly (approved antibodies) | Variable |
| Route | Endogenous; IV/SC (research) | Intrathecal, Intracerebroventricular (research) |
| FDA Status | Anti-CGRP antibodies approved (erenumab, fremanezumab, galcanezumab, eptinezumab) | Not approved |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.